Aza Rakhmanova

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Jan van Lunzen, Franco Maggiolo, José Ramón Arribas et al. · The Lancet Infectious Diseases · 2011 · 295 citations

Week Results, Treatment And Prevention, Antiviral Drug Development +7

Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

Amanda Mocroft, Peter Reiss, Jacek Gąsiorowski et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 271 citations

The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm – volume 2

Angelos Hatzakis, Vladimir Chulanov, Adrián Gadano et al. · Journal of Viral Hepatitis · 2015 · 124 citations · Full text

Viremic Population, Autoimmune Liver Disease, Viral Hepatitis +19

Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 2

V A Saraswat, Suzanne Norris, Robert J. de Knegt et al. · Journal of Viral Hepatitis · 2015 · 93 citations · Full text

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

Aza Rakhmanova, Ekaterina Doubovskaya, A. A. Yakovlev et al. · AIDS · 2003 · 80 citations